Summary
Background: Gastric cancer is often diagnosed in the metastatic stage, and only 10% of patients survive for as long as 2 years. Current chemotherapy regimens show significant treatment-related toxicities. It is crucial to identify the patients that will benefit most from certain chemotherapy regimens in order to avoid unnecessary side effects. Patients and Methods: 2 patients with advanced gastric cancer repeatedly received 5-FU/cisplatin combination chemotherapy. Genomic DNA was extracted from tumor tissue and mononuclear blood cells. Genotype analysis of genes of metabolizing and DNA repair enzymes was carried out using a PCR-RFLP technique. Direct sequencing was used to identify mutations of the gene dihydropyrimidine dehydrogenase (DPD). Results: Prolonged survival of 51 and 29 months, respectively were observed in our 2 patients. Both patients were positive for genotypes of thymidylate synthasethe target enzyme of 5-FU -that are associated with improved drug response. DPD variants connected with increased toxicity were not observed. However, both patients also showed genotypes in cisplatin metabolizing enzymes which enhance the effect of the drug. Conclusion: Genotype analysis in drug metabolizing enzymes of 5-FU and cisplatin provide a possible explanation for extraordinary therapy effects observed in 2 patients with advanced gastric cancer.
Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer -Report of 2 Cases Introduction
Gastric cancer is often diagnosed in advanced stages of the disease and is therefore associated with a poor prognosis. The median survival is as little as 6-8 months, and less than 10% of patients with metastatic disease survive for as long as 2 years [1] . Current treatment regimens -including epirubicin, methotrexat, platinum and 5-FU -are often highly toxic [2] . Recently, additional drugs such as irinotecan, taxanes and cetuximab have been introduced to palliative treatment of gastric cancer. The high toxicity and limited benefits of current chemotherapies for most gastric cancer patients require a careful selection of patients suitable for treatment. Currently, there are no efficient clinical, pathological or molecular markers to distinguish between responders and non-responders in relation to certain chemotherapy regimens used in gastric cancer. Pharmacogenetic analysis utilizes information on metabolic variations of administered chemotherapeutic drugs to predict clinical outcome. A combination of cisplatin and 5-FU is widely used in gastric cancer patients. Several functional genetic polymorphisms have been described for metabolizing enzymes of these substances such as thymidylate synthase (TS), glutathione S-transferase (GST) and excision cross complementing gene (ERCC) [3] . Here, we report on an extraordinary response to 5-FU/cisplatin combination chemotherapy in 2 gastric cancer patients. We further provide information on pharmacogenetic analysis demonstrating its potential as a predictor for clinical outcome in gastric cancer.
Case Reports
Clinical Observations A 51-year-old female patient (patient A) was diagnosed with advanced gastric cancer in February 2001. Initial surgery revealed advanced peritoneal carcinomatosis, and parts of the omentum, the adnexes and a Krukenberg's tumor were removed. A postoperative CT scan demonstrated advanced peritoneal carcinomatosis and a thickening of the stomach wall, but no further distant metastases. 6 weeks after surgery, a combination chemotherapy of 5-FU and cisplatin was initiated. The patient received 200 mg/m 2 leucovorin followed by 2000 mg/m 2 5-FU once weekly and 50 mg/m 2 cisplatin every other week for 6 weeks (one cycle). Tumor assessment after 3 cycles of chemotherapy revealed that all tumorrelated lesions had disappeared. Approximately 1 year after having been diagnosed, the patient once again showed tumor progression and a thickening of the stomach wall. The patient received 2 more cycles of chemotherapy followed by a Billroth II resection and remained diseasefree for 10 months. In May 2004, the disease recurred in the remaining stomach and the abdominal cavity. The patient received 3 more cycles of 5-FU/cisplatin and did not show any disease progression until November 2004. At that point, the chemotherapy regimen was changed to 5-FU, leucovorin and mitomycin C. The patient last visited the hospital in May 2005, 51 months after the initial diagnosis of stomach cancer and peritoneal carcinomatosis. During the entire treatment, no major hematological or gastrointestinal toxicities were observed. The patient did not demonstrate any hepatic or renal failure.
Patient B, a 60-year-old female patient, was diagnosed with stomach cancer in December 2002 after having reported constantly increasing digestive problems and pains in the upper abdomen. Clinical examination revealed a 22 × 26 mm mass on the right abdominal wall. The stomach was removed (R2 resection) in an attempt to prevent gastric outlet obstruction, and examination of biopsies taken from the mass on the abdominal wall confirmed metastasized stomach cancer. 7 weeks after surgery, palliative chemotherapy with 5-FU/cisplatin as described above was started. After 2 cycles of combination chemotherapy, CT scans showed only minimal residual disease, and complete response was obtained after 3 cycles, followed by a disease-free interval of 23 months. 1 month prior to a scheduled follow-up visit at the outpatient clinic, patient B noticed significant weight loss and new abdominal pain. In February 2005, the disease progressed including retroperitoneal lymph node metastases, and the patient was put back on 5-FU/cisplatin combination chemotherapy. Upon last patient contact in May 2005, no disease progression was observed. In addition to the remarkable response to the treatment, patient B experienced severe side effects in the form of WHO grade-III diarrhea. The diarrhea was managed with saline infusions and oral loperamide. Since the patient had responded well to the first therapy cycle, we aimed to continue the chemotherapy regimen. Tumor response was evaluated according to the RECIST criteria. Toxicity was graded based on the WHO toxicity criteria. Both patients gave informed consent to perform genotype analysis. Patients A and B showed remarkable responses to 5-FU/cisplatin chemotherapy with prolonged time to progression and survival times of 51 months and 29 months, respectively.
Pathological Examination and Genotype Analysis
Patient A showed a poorly differentiated adenocarcinoma of the stomach. The tumor of patient B was moderately differentiated. For genotyping, DNA was extracted from both tumor sections and peripheral mononuclear cells. Genotyping was performed using a PCR based restriction fragment length polymorphism (RFLP) technique and direct sequencing [4, 5] . Genetic polymorphisms were examined in the following genes involved in the metabolism of cisplatin and 5-FU: thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), glutathione S-transferase P1 (GSTP1) and excision repair cross complementing gene 1 (ERCC1). The genotypes are presented in table 1. Between tumor and host DNA, no genotype differences were observed.
Discussion
Both patients experienced prolonged survival and benefited significantly from repeated 5-FU/cisplatin combination chemotherapy. We analyzed functional genetic variations in the DNA sequence of metabolizing enzymes of 5-FU (TS-3', TS-5', DPD) and cisplatin (GSTP1-105, ERCC1-118). The TS-3' 1494del6 (-) variant and the TS-5' 2R and 3RC variants have been associated with decreased TS expression [6, 7] . Several reports link low TS expression levels to a favourable outcome of 5-FU based chemotherapy in gastrointestinal tumors including gastric cancer [8] [9] [10] . Patient A had TS genotypes (TS-3' and TS-5') associated with decreased TS levels, which may have enhanced the 5-FU action. Interestingly, no severe side effects were observed in this patient. High-grade hematological and gastrointestinal side effects have been described in patients with DPD deficiency [11] . The polymorphism in exon 14 of the DPD gene, that shows the highest frequency of known DPD polymorphisms and has been linked to even fatal toxicity, was not identified in our patients [4] . The dramatic side effects seen in DPD deficient patients are due to accumulation of active metabolites of 5-FU, since DPD clears more than 80% of 5-FU in the liver. However, patient B experienced grade-III diarrhea. Such an association between 5-FU toxicity and TS genotype contrary to the effects on the tumor has been reported before [12] . Although both patients harbored TS genotypes favoring tumor response and increased toxicity, only patient B demonstrated significant side effects. This reflects obvious limitations of a pharmacogenetic approach focusing on key enzymes. Functional variations in additional players such as methylentetrahydrofolate reductase (MTHFR) or dUTP dinucleotidohydrolase (dUTPase) may have neutralized the 5-FU effect in patient A but enhanced its power in patient B. Furthermore, it has to be considered that responses seen in both patients are the results of a combination chemotherapy of 5-FU and cisplatin.
The detoxifying effect of GSTP1 on cisplatin is well established [13] . The valine variant of a single nucleotide polymorphism (SNP) within exon 5 of the GSTP1 gene could be linked to superior survival in colorectal cancer patients that received 5-FU/platinum chemotherapy [14] . The favorable GSTP1 variant was detected in its homozygous form in patient A. Patient B was heterozygous for this polymorphism. In addition, both patients demonstrated ERCC1 genotypes that have been linked to impaired DNA repair capacity [15] . Taken together, both patients demonstrated genotypes that enhance the platinum effect due to less efficient detoxification of the administrated drug (GSTP1 genotype) and reduced repair of cisplatin-induced DNA adducts by the nucleotide excision repair pathway (ERCC1 genotype).
In conclusion, both patients with advanced gastric cancer experienced significant clinical benefit and extraordinary prolonged survival following 5-FU/cisplatin combination chemotherapy. Pharmacogenetic analysis of metabolizing enzymes provided some insight into possible mechanisms underlying this success. Since new drugs such as oxaliplatin [16] and docetaxel [17] have recently been shown to be effective in the treatment of patients with gastric cancer, pharmacogenetics appear to be a promising tool to tailor chemotherapy in these patients in the future. The clinical impact of pharmacogenetic analysis in patients with advanced gastric cancer is currently evaluated in large clinical trials. Our preliminary findings regarding polymorphisms in the TS and GSTP1 gene and response to 5-FU/cisplatin chemotherapy in these patients need to be confirmed before this information should be incorporated into clinical routine. 
